<DOC>
	<DOC>NCT02463643</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.</brief_summary>
	<brief_title>To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis, Peptic</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>In observation period, the participant must have endoscopically confirmed erosive esophagitis of Grade A to D, as defined by the LA classification grading system, and the target number of participants who are clearly Grade C or D is 20% (96 participants) or more of the total participants. Outpatient (including inpatient for examination) Participants with a previous or current history of eosinophilic esophagitis,scleroderma, esophageal stenosis, esophageal varices, Barrett's esophagus ( columnar epithelium metaplasia&gt;=3 cm ) or highgrade dysplasia.However, participants with Schatzki's ring ( &gt;=20mm ) are allowed to be included. Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer (mucosal defect with white coating&gt;=3mm) within 28 days prior to observation period . Participants with above disease at endoscopy during the observation period. Participants with ZollingerEllison syndrome.Participants with suspected gastric acid hypersecretion disorders attributable to hyperparathyroidism and others. Participants with a previous history of surgery of esophagus,stomach or duodenum (excluding removal of benign polyp by endoscopic polypectomy) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>